natgillin/translations-raw huggingface dataset:
Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare 
Zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
In this study 100% of animals were protected against homologous challenge, and 81% of animals were protected against heterologous challenge. 
V tej študiji je bilo pred homologno provokacijo zaščitenih 100 % živali in pred heterologno provokacijo 81 % živali.
As with all vaccines, AFLUNOV may not fully protect all persons who are vaccinated. 
Kot druga cepiva morda tudi cepivo AFLUNOV ne bo popolnoma zaščitilo vseh cepljenih oseb.
These studies provided limited immunogenicity data in subjects with some underlying medical (in particular, renal impairment and peripheral cardiovascular disease) and immunosuppressive conditions (in particular, transplant recipients and patients under cancer treatment). 
Ti študiji sta podali omejene podatke o imunogenosti pri osebah z nekaterimi osnovnimi bolezenskimi stanji (zlasti okvaro ledvic in periferno srčno-žilno boleznijo) in zmanjšanim imunskim odzivom (zlasti pri prejemnikih presadkov in bolnikih, ki se zdravijo zaradi raka).
In the absence of compatibility trials, this medicinal product must not be mixed with other medicinal products. 
Zaradi pomanjkanja študij kompatibilnosti cepiva ne smemo mešati z drugimi zdravili.
Lung damage was reduced in vaccinated groups. 
Poškodbe pljuč v cepljenih skupinah so bile manjše.
• Allergic reactions possibly with shortness of breath, wheezing, swelling of the throat, or leading to a dangerous decrease of blood pressure, which, if untreated, may lead to shock. 
• Alergijske reakcije, ki so lahko vključevale kratko sapo, sopenje, oteklost grla ali alergijske reakcije, ki povzročijo nevarno znižanje krvnega tlaka, ki lahko, če stanje ni zdravljeno,
However, in a pandemic situation, it may be appropriate for you to be vaccinated with AFLUNOV provided that appropriate medical treatment is immediately available in case of an allergic reaction. 
Vendar bo v primeru pandemije cepljenje s cepivom AFLUNOV za vas morda priporočljivo, če bo takoj na voljo ustrezna medicinska oprema za primer alergijske reakcije.
AFLUNOV may not fully protect everyone who is vaccinated, especially elderly subjects and those with weakened immune systems, such as HIV patients, or those with underlying long term medical problems, such as diabetes, lung disease or heart problems. 
Cepivo AFLUNOV vseh cepljenih oseb morda ne zaščiti povsem, še posebej starejših oseb in tistih z oslabljenim imunskim sistemom, kot so bolniki, okuženi z virusom HIV, ali bolniki z dolgotrajnimi osnovnimi bolezenskimi stanji, kot so diabetes, pljučna bolezen ali težave s srcem.
Paediatric population The safety and efficacy of AFLUNOV in subjects under 18 years of age have not yet been established. 
Varnost in učinkovitost cepiva AFLUNOV pri preiskovancih, starih do 18 let, še nista bili dokazani.
What AFLUNOV is and what it is used for What you need to know before you receive AFLUNOV How AFLUNOV is given 
Kaj je cepivo AFLUNOV in za kaj ga uporabljamo Kaj morate vedeti, preden boste cepljeni s cepivom AFLUNOV Kako se daje cepivo AFLUNOV
• Angioedema (abnormal swelling of the skin, usually around the eyes, lips, tongue, hands or feet, due to an allergic reaction). 
• angioedemom (nenormalno oteklostjo kože zaradi alergijske reakcije, ponavadi na območju oči, ustnic, jezika, dlani ali stopal).
All animals receiving 2 doses of AFLUNOV were protected, and 94% of animals receiving a single dose of AFLUNOV were protected. 
Zaščitene so bile vse živali, ki so prejele 2 odmerka cepiva AFLUNOV, in 94 % živali, ki so prejele en odmerek cepiva AFLUNOV.
In both studies, subjects with underlying medical and immunosuppressive conditions reported higher frequencies of diarrhoea, loss of appetite and vomiting compared to healthy subjects (irrespective of age). 
V obeh študijah so osebe z osnovnimi bolezenskimi stanji ali zmanjšanim imunskim odzivom poročale o večji pogostnosti driske, izgube apetita in bruhanja v primerjavi z zdravimi osebami (ne glede na starost).
Tell the doctor requesting these tests that you have recently been given AFLUNOV. 
Povejte zdravniku, ki je pregled naročil, da ste bili pred kratkim cepljeni s cepivom AFLUNOV.
Across all ages, low percentages of subjects reported fever. 
V vseh starostnih skupinah je bil odstotek poročane povišane telesne temperature nizek.
When a person is given the vaccine, the immune system (the body's natural defence system) will produce its own protection (antibodies) against the disease. 
Imunski sistem (naravni obrambni sistem telesa) osebe, ki dobi cepivo, začne izločati lastno zaščito (protitelesa) proti bolezni.
Gently shake before use. 
Pred uporabo nežno pretresite.
Allergic reactions, anaphylaxis including dyspnoea, bronchospasm, laryngeal oedema, in rare cases leading to shock. 
Alergijske reakcije, anafilaksa vključno z dispnejo, bronhospazem, edem grla, ki v redkih primerih povzročijo šok
AFLUNOV contains less than 1 mmol sodium (23 mg) and less than 1 mmol of potassium (39 mg) per 0.5 ml dose, i.e. essentially sodium- and potassium-free. 
Cepivo AFLUNOV vsebuje manj kot 1 mmol natrija (23 mg) in manj kot 1 mmol kalija (39 mg) na odmerek 0,5 ml, kar pomeni, da je v bistvu brez natrija in kalija.
Data in children and adolescents suggest a slight decrease in side effects after the second dose of the vaccine, with no increase in rates of fever. 
Podatki za otroke in mladostnike kažejo rahlo znižanje neželenih učinkov po drugem odmerku cepiva brez pogostejšega pojavljanja zvišane telesne temperature.
PSUR submission when AFLUNOV is used during an influenza pandemic: 
Predložitev PSUR za cepivo AFLUNOV med pandemijo gripe:
Adults and elderly (18 years of age and above): 
Odrasli in starejši bolniki (stari 18 let ali več):
• swelling, pain and redness at the injection site extending to more than 10 cm and lasting more than one week (Injection site cellulitis-like reaction) 
• Otekanje, bolečina in rdečina na mestu injiciranja na območju več kot 10 cm, ki traja več kot en teden (celulitisu podobna reakcija na mestu injiciranja).
Up to 50% (n=33) of the elderly subjects aged 62 to 88 years immunised with AFLUNOV in trial V87P1 were seroprotected at six months. 
Do 50 % (N = 33) starejših oseb, starih od 62 let do 88 let ter imuniziranih s cepivom AFLUNOV v preskušanju V87P1, je bilo v šestem mesecu serozaščitenih.
The vaccine contains per 0.5 ml 9.75 mg squalene, 1.175 mg polysorbate 80, 1.175 mg sorbitan trioleate. 
Cepivo vsebuje na 0,5 ml 9,75 mg skvalena, 1,175 mg polisorbata 80 in 1,175 mg sorbitantrioleata.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
• Swollen lymph nodes, palpitations (irregular or forceful heart beat), tachycardia (faster than normal heart beat), weakness, pain in the extremities, cough and asthenia (unusual weakness). 
• Otekle bezgavke, palpitacije (neredno ali močno bitje srca), tahikardija (hitrejše bitje srca kot normalno), slabotnost, bolečina okončin, kašelj in astenija (neobičajna oslabelost)
Children (3-<9 years) 
Otroci (3-< 9 let)
In toddlers, erythema and tenderness were the most commonly reported solicited local reactions; irritability and unusual crying were the most commonly reported solicited systemic reactions. 
Pri malčkih so bile najpogostejše pričakovane lokalne reakcije eritem in napetost; razdražljivost in neobičajen jok sta bili najpogosteje poročani pričakovani sistemski reakciji.
One dose of 0.5 ml contains: Influenza virus surface antigens (haemagglutinin and neuraminidase), propagated in fertilised hens' eggs from healthy chicken flocks, of strain: 
En odmerek (0,5 ml) vsebuje: površinske antigene (hemaglutinin in nevraminidaza) virusa influence, namnoženega v oplojenih kokošjih jajcih iz jat zdravih piščancev, seva:
In both trials, immunogenicity of AFLUNOV was shown by HI, SRH and MN assays following both the first and second dose. 
V obeh preskušanjih so dokazali imunogenost cepiva AFLUNOV s testi HI, SRH in MN po prvem in po drugem odmerku.
V87P11 Adults (18-60 years) N=186 
V87P11 odrasli (18-60 let) N = 186
Results are shown by SRH. 
Rezultati so prikazani s testom SRH.
Fever ≥ 38°C (≥ 40°C) 
vsi lokalni sistemski zvišana telesna temperatura ≥ 38 °C (≥ 40 °C)
One dose of 0.5 ml at an elected date. 
En odmerek 0,5 ml se uporabi na izbrani dan.
In the event of an officially declared influenza pandemic due to A/H5N1 virus, persons previously vaccinated with one or two doses of AFLUNOV that contained haemagglutinin (HA) antigen derived from a different clade of the same influenza subtype as the influenza pandemic strain may receive a single dose of AFLUNOV instead of two doses that are required in previously unvaccinated individuals (see section 5.1). 
V primeru uradne objave pandemije gripe zaradi virusa A/H5N1 lahko osebe, predhodno cepljene z enim ali dvema odmerkoma cepiva AFLUNOV, ki vsebuje hemaglutininski (HA) antigen, izpeljan iz drugačne gruče enakega podtipa gripe kot pandemski sev gripe, prejmejo en odmerek cepiva AFLUNOV namesto dveh, ki sta potrebna za predhodno necepljene osebe (glejte poglavje 5.1).
After shaking, the normal appearance of AFLUNOV is a milky-white suspension. 
Normalen videz cepiva AFLUNOV po pretresanju je mlečno bela suspenzija.
In trial V87_25 and V87_26, 96 and 67 subjects, respectively, were over the age of 70 years. 
V preskušanju V87_25 oziroma V87_26 je bilo 96 oseb oziroma 67 oseb starejših od 70 let.
Heterologous immune response against A/Indonesia/5/2005 (clade 2.1) was detectable in study V87P11 after the second vaccination, indicating cross-reactivity of the clade 2.2.1 vaccine against clade 2.1 strains. 
Heterologni imunski odziv na A/Indonesia/5/2005 (gruča 2.1) so zaznali v študiji V87P11 po drugem cepljenju, kar kaže na križno reaktivnost cepiva gruče 2.2.1 proti sevom gruče 2.1.
• Vasculitis (inflammation of the blood vessels which can cause skin rashes, joint pain and kidney problems) 
• Vaskulitis (vnetje krvnih žil, ki lahko povzroči kožne izpuščaje, bolečine v sklepih in težave z ledvicami).
However, it is estimated that during the 2009 H1N1 pandemic more than 90,000 women were vaccinated during pregnancy with Focetria (an H1N1 pandemic vaccine similar to AFLUNOV) which contains the same amount of adjuvant MF59C.1 as AFLUNOV. 
Vendar se ocenjuje, da je bilo med pandemijo H1N1 leta 2009 med nosečnostjo cepljenih več kot 90.000 žensk s cepivom Focetria (pandemsko cepivo H1N1, podobno cepivu AFLUNOV), ki vsebuje enako količino adjuvansa MF59C.1 kot cepivo AFLUNOV.
In these trials, lower levels of antibodies and reduced seroprotection rates against homologous H5N1 A/turkey/Turkey/1/2005 were also measured in healthy elderly subjects, as compared to healthy adults, though previous studies showed induction of sufficiently immunogenic responses against H5N1 strains (see above for information on elderly). 
V teh preskušanjih so tudi pri zdravih starejših osebah izmerili nižje ravni protiteles in znižane ravni serozaščite proti homolognemu sevu H5N1 A/turkey/Turkey/1/2005 v primerjavi z zdravimi odraslimi osebami, čeprav so prejšnje študije pokazale vzpostavitev zadostnih imunogenih odzivov proti sevom H5N1 (glejte zgoraj za informacije o starejših osebah).
A study in rabbits did not indicate reproductive or developmental toxicity of AFLUNOV (see section 5.3). 
Študija pri kuncih ni pokazala vpliva cepiva AFLUNOV na sposobnost razmnoževanja ali razvoja (glejte poglavje 5.3).
administered 12 months following the first dose, was higher than after both first and second doses. 
Reaktogenost po tretjem odmerku, danem 12 mesecev po prvem odmerku, je bila višja kot po obeh, prvem in drugem odmerku.
Subjects with underlying medical or immunosuppressive conditions: 
Osebe z osnovnimi bolezenskimi stanji ali zmanjšanim imunskim odzivom:
However, in a pandemic situation caused by the strain included in this vaccine, it may be appropriate to give this vaccine to individuals with a history of anaphylaxis as defined above, provided that facilities for resuscitation are immediately available in case of need. 
Vendar pa je lahko v pandemski situaciji, ki jo povzroči sev, vključen v to cepivo, posameznika z anafilakso v anamnezi, kot je opredeljeno zgoraj, ustrezno cepiti, če je v takšnem primeru takoj na voljo oprema za reševanje.
Limited data were obtained from women who became pregnant during the course of clinical trials with AFLUNOV or similar pandemic H1N1v vaccines adjuvanted with MF59C.1. 
Pridobili so omejene podatke pri ženskah, ki so zanosile v teku kliničnih preskušanj s cepivom AFLUNOV ali podobnimi pandemskimi cepivi H1N1v z adjuvansom MF59C.1.
Data on safety of a booster dose of AFLUNOV are limited to three trials (V87P1, V87P2 and V87P1E1) that included 116 adults (18-60 years) and 56 elderly subjects (>61 years). 
Podatki o varnosti obnovitvenega odmerka cepiva AFLUNOV so omejeni na tri preskušanja (V87P1, V87P2 in V87P1E1), v katera je bilo vključenih 116 odraslih (18-60 let) in 56 starejših oseb (≥ 61 let).
The vaccine should under no circumstances be administered intravascularly or intradermally. 
V nobenem primeru se ne sme cepiva dati intravaskularno ali intradermalno.
Undesirable effects in patients with underlying long term medical problems such as diabetes, lung disease or heart problems and weakened immune systems (immunocompromised) such as HIV patients 
Neželeni učinki pri bolnikih z dolgotrajnimi osnovnimi bolezenskimi stanji, kot so diabetes, pljučna bolezen ali težave s srcem, in oslabljenim imunskim sistemom, kot pri bolnikih, okuženih z virusom HIV (imunsko oslabljenih bolnikih)
The adverse reaction rates reported after any vaccination doses (i.e. 1st, 2nd or booster) were similar and are listed according to the following MedDRA frequency convention and system organ class: 
Seznam neželenih učinkov Stopnje neželenih učinkov, o katerih so poročali po katerem koli odmerku cepljenja (tj. 1., 2. ali obnovitvenem), so bile podobne in so naštete glede na naslednjo opredelitev pogostnosti in organskih sistemov po MedDRA:
• Neuritis (inflammation of nerves) 
• nevritis (vnetje živcev).
(≥1/10,000 to 
(≥ 1/1.000 do
0.5 ml in pre-filled syringe (type I glass) with plunger-stopper (bromo-butyl rubber). 
0,5 ml v napolnjeni injekcijski brizgi (steklo tipa I) z zamaškom na batu (bromobutilna guma).
• Low blood platelet count which can result in bleeding or bruising. 
• Zmanjšano število trombocitov v krvi, kar lahko povzroči krvavitve ali modrice.
• Headache, dizziness, drowsiness, fainting. 
• Glavobol, omotičnost, zaspanost, omedlevica
Neurological disorders such as 
• Nevrološke motnje, kot so:
The other ingredients are: sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, sodium citrate, citric acid and water for injections. 
Druge sestavine zdravila so: natrijev klorid; kalijev klorid; kalijev dihidrogen fosfat; dinatrijev fosfat dihidrat; magnezijev klorid heksahidrat; kalcijev klorid dihidrat, natrijev citrat, citronska kislina in voda za injekcije.
Efficacy against challenge with virus homologous and heterologous to vaccine strains was evaluated in the ferret model. 
Učinkovitost proti provokaciji z virusom, homolognim in heterolognim na cepilne seve, so ocenili pri belem dihurju.
In children and adolescents, pain was the most frequently reported solicited local reaction, and fatigue and headache were the most commonly reported solicited systemic reactions. 
Pri otrocih in mladostnikih je bila najpogosteje poročana lokalna reakcija bolečina, najpogosteje poročani pričakovani sistemski reakciji pa sta bili utrujenost in glavobol.
If they persist, CONSULT YOUR DOCTOR. 
Če ne izzvenijo, SE POSVETUJTE
SP= seroprotection SC= seroconversion 
SK = serokonverzija
A third (booster) dose of AFLUNOV was administered 6 months onwards after the primary vaccination. 
Tretji (obnovitveni) odmerek cepiva AFLUNOV je bil dan po 6 ali več mesecih po primarnem cepljenju.
This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing A/turkey/Turkey/1/2005 (H5N1)-like strain (see sections 4.4 and 5.1). 
Ta indikacija temelji na podatkih o imunogenosti za zdrave osebe, stare 18 let ali več, po cepljenju z dvema odmerkoma cepiva, ki vsebuje sevu A/turkey/Turkey/1/2005 (H5N1) podoben sev (glejte poglavji 4.4 in 5.1).
A slight increase in reactions in adults was reported when a booster dose was administered 18 months after the initial dosing series. 
Poročali so o rahlem povečanju reakcij pri odraslih, ki so obnovitveni odmerek prejeli 18 mesecev po prvi seriji odmerkov.
The following additional adverse events were reported from post-marketing surveillance with seasonal non-adjuvanted trivalent vaccines in all age groups and a seasonal trivalent MF59-adjuvanted subunit influenza vaccine approved for use in elderly subjects 65 years of age and older: 
Pri spremljanju v obdobju trženja so poročali o naslednjih neželenih učinkih pri sezonskih trivalentnih cepivih brez adjuvansov v vseh starostnih skupinah in pri sezonskem trivalentnem komponentnem cepivu z adjuvansom MF59, ki je odobreno za uporabo pri starejših osebah, starih 65 let in več:
Immunization shall be postponed in patients with febrile illness or acute infection. 
Imunizacijo pri bolnikih s povišano telesno temperaturo ali akutno okužbo je treba preložiti.
In the elderly, the reported reactions increased with the third booster dose only when compared with the second dose. 
Pri starejših osebah je bilo pri tretjem obnovitvenem odmerku več poročil o reakcijah le v primerjavi z drugim obnovitvenim odmerkom.
After 3 weeks from the 2nd vaccination (day 43) all age groups (i.e. 6-35 months, 3-8 years and 9-17 years) achieved high levels of antibodies to (A/Vietnam/1194/2004) as evaluated with SRH and HI assays as presented in table below. 
Po 3 tednih od 2. cepljenja (43. dan) so vse starostne skupine (tj. 6-35 mesecev, 3-8 let in 9-17 let) dosegle visoko raven protiteles na sev (A/Vietnam/1194/2004), ocenjeno s testoma SRH in HI, kot je predstavljeno v spodnji preglednici.
Please inform your doctor or nurse if you have a bleeding problem or bruise easily. 
Obvestite zdravnika ali medicinsko sestro, če imate motnjo strjevanja krvi ali ste nagnjeni k podplutbam.
Immune response to vaccination assessed by MN assay is in line with results obtained with SRH. 
Imunski odziv na cepljenje, ocenjeno s testom MN, je v skladu z rezultati, pridobljenimi s SRH.
The vaccine should be allowed to reach room temperature before use. 
Pred uporabo počakajte, da cepivo doseže sobno temperaturo.
No data are available in children aged less than 6 months. 
Podatkov pri otrocih, starih do 6 mesecev, ni na voljo.
No increase in reactions was reported when a booster dose was administered 6 months-18 months later, after the initial dosing series. 
Niso poročali o povečanju števila neželenih učinkov ob dajanju tretjega odmerka 6 mesecev-18 mesecev kasneje po seriji začetnih odmerkov.
Vascular disorders Vasculitis with transient renal involvement. 
Žilne bolezni Vaskulitis s prehodno vpletenostjo ledvic
Injection 2 
2. injekcija
Your doctor needs to assess the benefits and potential risks of giving you the vaccine. 
Vaš zdravnik bo presodil razmerje med koristmi in možnimi tveganji cepljenja.
If co-administration with another vaccine is considered, immunisation should be carried out on separate limbs. 
Če je potrebna sočasna uporaba z drugim cepivom, je treba imunizacijo opraviti na drugi okončini.
SRH seroprotection rates ranged from 86% to 98%, seroconversion rated from 64% to 90%, and GMR ranged from 2.92 to 4.57. 
98 %, stopnje serokonverzije so bile v razponu od 64 % do 90 % in GMR je bilo v razponu od 2,92 do 4,57.
The incidence of AFLUNOV (A/Vietnam/1194/2004) adverse reactions has been evaluated in one clinical trial (V87P6) in children (6 months to 17 years old). 
Pojavnost neželenih učinkov pri cepivu AFLUNOV (A/Vietnam/1194/2004) so ovrednotili v enem kliničnem preskušanju (V87P6) pri otrocih (starih od 6 mesecev do 17 let).
Injection 1 
1. injekcija
Two doses of AFLUNOV were administered three weeks apart and a third dose 12 months following the first dose. 
V časovnem presledku treh tednov so dali dva odmerka cepiva AFLUNOV in tretji odmerek 12 mesecev po prvem odmerku.
AFLUNOV has been evaluated in healthy adults (18-60 years of age) and healthy elderly (over 60 years of age) following a 1, 22 day primary vaccination schedule, and booster vaccination (see sections 4.8 and 5.1). 
Cepivo AFLUNOV je bilo ovrednoteno pri zdravih odraslih (starih med 18 in 60 let) in zdravih starejših odraslih (starih več kot 60 let) po režimu primarnega cepljenja 1. in 22. dan in obnovitveno cepljenje (glejte poglavji 4.8 in 5.1).
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. 
Tako kot pri vseh cepivih, ki se injicirajo, je treba zagotoviti ustrezno obliko zdravljenja in zdravniškega nadzora, ki bi bila v primeru anafilaktične reakcije na cepljenje nemudoma na voljo.
Data obtained in adults showed that AFLUNOV can be given at the same time as non-adjuvanted seasonal influenza vaccines. 
Podatki, pridobljeni pri odraslih, kažejo, da se lahko cepivo AFLUNOV daje sočasno s sezonskimi cepivi proti gripi, ki ne vsebujejo adjuvansa.
General disorders and administration site conditions Extensive swelling of injected limb lasting more than one week, injection-site cellulitis-like reaction (some cases of swelling, pain, and redness extending more than 10 cm and lasting more than 1 week). 
Obsežna, več kot 1 teden trajajoča oteklina okončine, v katero je bilo injicirano cepivo; celulitisu podobna reakcija na mestu injiciranja (nekaj primerov otekline, bolečine in rdečine na območju več kot 10 cm in s trajanjem več kot 1 teden).
1.175 milligrams per 0.5 ml sorbitan trioleate 
1,175 miligrama na 0,5 ml sorbitantrioleat
Toddlers (6-<36 months) 
Malčki (6-< 36 mesecev)
* Seroprotection: SRH area ≥ 25 mm2 
* Serozaščita: površina SRH ≥ 25 mm2.
A single vaccination with AFLUNOV (A/Vietnam/1194/2004) induced high and rapid serological response in subjects primed 6-8 years previously with two doses of a different surrogate H5N vaccine, having same formulation as AFLUNOV but using the strain H5N3. 
Eno cepljenjem s cepivom AFLUNOV (A/Vietnam/1194/2004) je povzročilo visok in hiter serološki odziv pri osebah, ki so bile 6-8 let pred tem primarno imunizirane z dvema odmerkoma različnih nadomestnih cepiv za H5N, z enako formulacijo kot cepivo AFLUNOV, a s sevom H5N3.
Protection against influenza There is no immune correlate of protection established for influenza A (H5N1). 
Povezava med imunskim odzivom in zaščito pred gripo tipa A (H5N1) ni znana.
Potassium chloride (E508) Potassium dihydrogen phosphate (E340) Disodium phosphate dihydrate (E339) Magnesium chloride hexahydrate (E511) Calcium chloride dihydrate (E 509) Sodium citrate (E311) Citric acid (E330)Water for injections. 
natrijev klorid kalijev klorid (E508) kalijev dihidrogenfosfat (E340) dinatrijev hidrogenfosfat (E339) magnezijev klorid heksahidrat (E511) kalcijev klorid dihidrat (E509) natrijev citrat (E311) citronska kislina (E330) voda za injekcije
If administration of AFLUNOV with other vaccines can not be avoided, the vaccines should be injected into separate limbs. 
Če se cepljenju s cepivom AFLUNOV hkrati z drugimi cepivi ni mogoče izogniti, je treba cepivi injicirati vsako v svojo okončino.
a actual age range of population enrolled 
a dejanski razpon starosti vključene populacije
Medical Conditions N=140 
Bolezenska stanja N = 140
What AFLUNOV looks like and contents of the pack 
Izgled cepiva AFLUNOV in vsebina pakiranja
• Diarrhoea 
• diareja.